| Literature DB >> 31460232 |
Muhammed Ossama1, Rania M Hathout2, Dalia A Attia1, Nahed D Mortada2.
Abstract
The cytotoxic potential of allicin was evaluated on different cancer cell lines, particularly, hepatic (HepG-2), breast (MCF-7), lung (A-549), and prostatic (PC-3), where allicin scored an IC50 score of 19.26 μM on HepG-2. In order to increase the cell uptake, optimized allicin-loaded gelatin nanoparticles (GNPs) were prepared where the optimum formulation was surface-conjugated to glycyrrhetinic acid. GNPs were optimized using a D-optimal design. The optimum formulation had a particle size of 370.7 ± 6.78 nm and polydispersity index of 0.0363 ± 0.009 and 39.13 ± 2.38% of drug entrapment. The conjugation of the ligand, glycyrrhetinic acid with allicin-loaded GNPs, was confirmed utilizing 1H NMR. Drug release profiles in the presence/absence of collagenase were obtained. Finally, a cytotoxicity study on HepG-2 was performed for the unconjugated and conjugated allicin-loaded GNPs scoring IC50 of 10.95 and 5.046 μM, revealing two- and fourfold enhancements in allicin cytotoxicity, respectively. To our knowledge, the ligand-carrier pair, glycyrrhetinic acid-gelatin, was not explored before, and the developed system poses a successful liver cancer therapy.Entities:
Year: 2019 PMID: 31460232 PMCID: PMC6648216 DOI: 10.1021/acsomega.9b01580
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Figure 1Evaluation of the cytotoxic potential of allicin on: (A) human hepatocellular cancer cell line HepG-2, (B) human breast cancer cell line MCF-7, (C) human lung cancer cell line, and (D) human prostatic cancer cell line.
Optimization of GNPs Using the D-Optimal Experimental Design
| run | GA % | CLT (h) | stirring speed (rpm) | mean P.S. (nm) ± SD | mean PDI ± SD |
|---|---|---|---|---|---|
| 1 | 33.30 | 16.00 | 1000.00 | 786.1 ± 100.4 | 0.1785 ± 0.005 |
| 2 | 66.70 | 16.00 | 700.00 | 629.75 ± 4.74 | 0.307 ± 0.034 |
| 3 | 66.70 | 4.00 | 700.00 | 389.85 ± 2.89 | 0.057 ± 0.033 |
| 4 | 50.00 | 7.00 | 1150.00 | 402.22 ± 2.83 | 0.1635 ± 0.013 |
| 5 | 33.30 | 4.00 | 1000.00 | 663.55 ± 8.69 | 0.535 ± 0.069 |
| 6 | 33.30 | 16.00 | 700.00 | 740.45 ± 1.2 | 0.3645 ± 0.036 |
| 7 | 66.70 | 16.00 | 1300.00 | 566.7 ± 0.14 | 0.2515 ± 0.043 |
| 8 | 66.70 | 16.00 | 700.00 | 622.4 ± 0.85 | 0.1115 ± 0.153 |
| 9 | 50.00 | 10.00 | 850.00 | 416.84 ± 8.88 | 0.3215 ± 0.027 |
| 10 | 33.30 | 4.00 | 1300.00 | 431.5 ± 2.12 | 0.148 ± 0.132 |
| 11 | 33.30 | 10.00 | 1300.00 | 385.5 ± 21.25 | 0.3895 ± 0.062 |
| 12 | 66.70 | 4.00 | 700.00 | 370.7 ± 6.78 | 0.0363 ± 0.009 |
| 13 | 33.30 | 4.00 | 700.00 | 478.25 ± 3.04 | 0.473 ± 0.0255 |
| 14 | 50.00 | 16.00 | 1300.00 | 378.8 ± 1.55 | 0.122 ± 0.029 |
| 15 | 66.70 | 4.00 | 1300.00 | 547.65 ± 12.79 | 0.129 ± 0.0594 |
| 16 | 33.30 | 10.00 | 1300.00 | 388 ± 2.98 | 0.405 ± 0.064 |
Figure 2TEM images for the prepared allicin-loaded GNPs at a magnification power of 50 000× for (A,C) and 25 000× for (B).
Figure 3In vitro release profiles of allicin from the prepared GNPs in PBS of pH 7.4 with and without collagenase.
Figure 4Cytotoxicity of unconjugated and conjugated allicin-loaded GNPs on HepG-2 cells.
Figure 5Interaction of glycyrrhetinic acid with the ASGPR. Molecular docking displayed in (A) 2D and (B) 3D images.